Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other financing activities (2017)

Amicus Therapeutics' Other financing activities history spans 3 years, with the latest figure at $23.1 million for Q4 2017.

  • For the quarter ending Q4 2017, Other financing activities changed N/A year-over-year to $23.1 million, compared with a TTM value of $23.1 million through Sep 2018, up 16619.57%, and an annual FY2017 reading of $23.1 million, up 31.98% over the prior year.
  • Other financing activities for Q4 2017 was $23.1 million at Amicus Therapeutics, up from $28000.0 in the prior quarter.
  • The five-year high for Other financing activities was $23.1 million in Q4 2017, with the low at $28000.0 in Q1 2017.
  • Average Other financing activities over 3 years is $5.8 million, with a median of $110000.0 recorded in 2013.